Last reviewed · How we verify

NCT05328778

Pharmacokinetics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade in Patients During Laparoscopic Surgery

Status unknown Phase 4 Last updated 14 April 2022
What this trial tests

Phase 4 trial testing Sugammadex in Pharmacokinetics in 48 participants. Status unknown.

Timeline
16 July 2019
Primary endpoint
30 November 2022
30 November 2022

Quick facts

Lead sponsorGuangzhou General Hospital of Guangzhou Military Command
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment48
Start date16 July 2019
Primary completion30 November 2022
Estimated completion30 November 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Guangzhou General Hospital of Guangzhou Military Command

Who can join

Adults 18 to 70, any sex, with Pharmacokinetics. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to illustrate pharmacokinetics of sugammadex in reversal of vecuronium-induced neuromuscular blockade in patients during laparoscopic surgery

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sugammadex

Trials testing the same drug.

Other recruiting trials for Pharmacokinetics

Currently open trials in the same condition.

Other Guangzhou General Hospital of Guangzhou Military Command trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05328778.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing